Panobinostat and ruxolitinib in patients with myelofibrosis.

• Research type

  Research Study

• Full title

  A Phase 1b, open-label, multi-center, single arm, dose finding study to assess safety and pharmacokinetics of the oral combination of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF), post-polycythemia veramyelofibrosis (PP-MF) or post-essential thrombocythemiamyelofibrosis (PET-MF)

• IRAS ID

  84811

• Sponsor organisation

  Novartis Pharmaceuticals UK Ltd

• Eudract number

  2011-000861-10

• ISRCTN Number

  n/a

• Clinicaltrials.gov Identifier

  n/a

• Research summary

  This is a Phase 1b, open-label, multi-center, single arm, dose finding study to find out if the drug combination of panobinostat and ruxolitinib is safe and has beneficial effects in people who have Myelofibrosis. All patients will receive panobinostat and ruxolitinib. Approximately 40-58 patients in this study will be recruited from multiple centres around the world.

• REC name

  London - City & East Research Ethics Committee

• REC reference

  11/LO/1303

• Date of REC Opinion

  17 Oct 2011

• REC opinion

  Favourable Opinion